Treace Medical Concepts, Inc. Stock Price, News & Analysis

Treace Medical Concepts (TMCI) announced positive interim findings from the ALIGN3D™ clinical study on their Lapiplasty® 3D Bunion Correction™ procedure at the 2021 AOFAS Annual Meeting. The study, involving 151 participants, reported an average early weight-bearing return at 8.3 days, significant pain reduction, and a low recurrence rate of only 0.9% at 12 months. Patients also returned to work within 4 weeks and full activity within 4.1 months. Treace continues to strengthen its clinical evidence supporting the Lapiplasty® System, aimed at enhancing bunion surgery outcomes.

Treace Medical Concepts (TMCI) has launched the Adductoplasty™ System, a comprehensive approach for midfoot deformity correction in bunion patients. This system combines implants and precision instruments to ensure consistent realignment and stabilization of the midfoot, which affects up to 30% of hallux valgus cases. CEO John T. Treace highlighted the system's potential to enhance treatment for patients with combined bunion and midfoot issues, addressing a market gap in surgical solutions.

Treace Medical Concepts (TMCI) announced that CEO John T. Treace and CFO Mark Hair will join a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at approximately 4:15 PM ET. This discussion will focus on the company’s innovative Lapiplasty® 3D Bunion Correction™ procedure, designed to improve surgical treatment for bunions. A live webcast and replay will be available on the company's investor relations website.

Treace Medical Concepts (Nasdaq: TMCI), a pioneering orthopaedic medical device company, announced new data will be presented at the 2021 AOFAS Annual Meeting on September 22-25. The presentation will feature an interim analysis from the ALIGN3D™ clinical study, which evaluates the Lapiplasty® 3D Bunion Correction™ procedure. Lead author Dr. Dane Wukich will discuss outcomes from this multicenter study, focusing on patient recovery and radiographic results. The study aims to confirm effective bunion correction over a 24-month follow-up with 173 enrolled patients.

Treace Medical Concepts (TMCI) reported Q2 2021 revenue of $20.7 million, marking a 167% increase compared to Q2 2020. The gross margin improved to 80.9%, up 780 basis points year-over-year. The rise in revenue is attributed to more Lapiplasty® procedure kits sold and a growing customer base. Despite higher revenues, the net loss for the quarter increased to ($5.1 million), or ($0.10) per share, compared to ($2.1 million), or ($0.06) per share last year. The company anticipates full-year revenue between $90 million and $95 million, reflecting a growth of 57% to 65%.

Treace Medical Concepts (NasdaqGS: TMCI) will announce its second quarter 2021 financial results on August 5, 2021, after the market closes. A conference call led by management will commence at 4:30 p.m. ET to discuss the results. The company is known for its Lapiplasty® 3D Bunion Correction™ system, which addresses bunion deformities. Investors can join the call by dialing (888) 708-0264 or (720) 405-2122 for international access. The call will also be webcasted live and archived on their investor relations website.

Treace Medical Concepts (TMCI) reported significant first-quarter 2021 financial results, achieving $18.7 million in revenue, a 66.2% increase from last year. Gross margin improved to 82.2%, up 340 basis points year-over-year, driven by higher sales of the Lapiplasty Procedure Kits. Despite a net loss of $2.6 million or ($0.07) per share, the company anticipates a full-year revenue range of $87 million to $92 million, indicating 52% to 60% growth from fiscal 2020. Cash and equivalents stood at $16.2 million as of March 31, 2021, excluding IPO proceeds.

Treace Medical Concepts (TMCI) announced positive interim results from the ALIGN3D clinical study at the ACFAS Annual Scientific Conference. The study evaluated 128 participants undergoing the Lapiplasty 3D Bunion Correction procedure. Key findings include an early weight-bearing average of 8.3 days, a 1.4% recurrence rate at 12 months, and significant improvements in patient-reported pain and quality of life. The study aims to assess long-term outcomes and has completed enrollment, with final results expected in 2023.

Treace Medical Concepts (TMCI) announced it will release its Q1 2021 financial results on May 25, 2021, after market close. A conference call hosted by management will take place at 4:30 p.m. ET to discuss these results. Investors can access the call by dialing (833) 730-3977 (domestic) or (720) 405-2122 (international) with Conference ID: 1157038. The company specializes in surgical treatments for bunions through its patented Lapiplasty® 3D Bunion Correction™ system, aimed at enhancing patient recovery and addressing the root causes of bunion deformities.